WO2000002916B1 - PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY - Google Patents
PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITYInfo
- Publication number
- WO2000002916B1 WO2000002916B1 PCT/US1999/015432 US9915432W WO0002916B1 WO 2000002916 B1 WO2000002916 B1 WO 2000002916B1 US 9915432 W US9915432 W US 9915432W WO 0002916 B1 WO0002916 B1 WO 0002916B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- canceled
- tgf
- pharmaceutical composition
- collagen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compositions suitable for pharmaceutical administration are provided in which one compound is a small peptide mimic of TGF-β. More preferably, pharmaceutical compositions of the present invention are formulated as combinations of two components, wherein one component includes a peptide mimic for TGF-β and the other component is structurally or biologically analogous to a small region of collagen and mimics the conformation recognized by collagen binding species. A particularly preferred combinations is A-N-V-A-E-N-A (SEQ ID NO:1) and G-G-T-P-G-P-Q-G-I-A-G-Q-R-G-V-V (SEQ ID NO:17).
Claims
29
AMENDED CLAIMS
[received by the International Bureau on 6 March 2000 (06.03.00); original claims 1-9 cancelled; remaining claims unchanged (3 pages)]
CANCELED.
2. CANCELED.
3. CANCELED.
4. CANCELED.
CANCELED.
CANCELED.
7. CANCELED. 30
CANCELED.
9. CANCELED.
10. A pharmaceutical composition comprising a TGF-β mimic and a collagen receptor agonist, the TGF-β mimic being selected from the group consisting of:
L-I- A-K-G-K (SEQ ID NO : 16) I-(Aib)-A-E-A-K (SEQ ID NO: 18)
L-(Abu)-A-E-A-K (SEQ ID NO: 19)
L-P-A-E-A-K (SEQ ID NO:20)
L-I-P-E-A-K (SEQ ID NO:21)
L-I-(Aib)-E-A-K (SEQ ID NO:22) L-I-A-(Aib)-E-A (SEQ ID NO:23)
I-W-G-L-D-G-(bAla)-K (SEQ ID NO:24)
W-I-A-L-E-G-(bAla)-K (SEQ ID NO:25) L-I-(D-Ala)-E-A-K L-I-A-(D-Glu)-A-K L-I-A-P-(D-Glu)-A L-I-A-(X. A-K where Xx is trans-4-hydroxyproline.
11. The pharmaceutical composition as in claim 10 wherein the collagen receptor agonist has enhanced cell binding with respect to collagen. 31
12. The pharmaceutical composition as in claim 11 wherein the collagen receptor agonist has a domain that mimics collagen binding to cells.
13. The pharmaceutical composition as in claim 10 wherein each of the TGF-β mimic and the collagen receptor agonist is in an amount of from 1 μg/kg to 10 mg/kg of patient weight.
14. The pharmaceutical composition as in claim 13 wherein the collagen receptor agonist has the sequence G-T-P-G-P-Q-G-I-A-G-Q-R-G-N-N (SEQ ID NO: 17).
15. A pharmaceutical composition comprising: A-N-V-A-E-N-A(SEQ ID NO: l)and G-T-P-G-P-Q-G-I-A-G-Q-R- G-N-N (SEQ ID NO: 17) in a physiologically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU49762/99A AU4976299A (en) | 1998-07-10 | 1999-07-08 | Peptide compositions mimicking tgf-beta activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/113,696 US6638912B2 (en) | 1995-05-01 | 1998-07-10 | Peptide compositions mimicking TGF-β activity |
| US09/113,696 | 1998-07-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2000002916A2 WO2000002916A2 (en) | 2000-01-20 |
| WO2000002916A3 WO2000002916A3 (en) | 2000-04-13 |
| WO2000002916B1 true WO2000002916B1 (en) | 2000-05-18 |
Family
ID=22350965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1999/015432 WO2000002916A2 (en) | 1998-07-10 | 1999-07-08 | PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6638912B2 (en) |
| AU (1) | AU4976299A (en) |
| WO (1) | WO2000002916A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0002364D0 (en) * | 2000-06-22 | 2000-06-22 | Pharmacia & Upjohn Ab | Growth Factors |
| US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
| US8697139B2 (en) | 2004-09-21 | 2014-04-15 | Frank M. Phillips | Method of intervertebral disc treatment using articular chondrocyte cells |
| US20060293227A1 (en) * | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Cosmetic compositions and methods using transforming growth factor-beta mimics |
| US20060293228A1 (en) * | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Therapeutic compositions and methods using transforming growth factor-beta mimics |
| US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
| KR100824396B1 (en) * | 2006-10-10 | 2008-04-22 | (주)케어젠 | Peptides Having Activities of Epidermal Growth Factor and Its Uses |
| KR100982179B1 (en) | 2008-06-23 | 2010-09-14 | (주)케어젠 | Peptides Having Activities of Transforming Growth Factor-Beta and Their Uses |
| US8241623B1 (en) | 2009-02-09 | 2012-08-14 | David Bermudes | Protease sensitivity expression system |
| WO2010119997A1 (en) | 2009-04-14 | 2010-10-21 | (주)케어젠 | Peptide having activity of transforming growth factor and production method therefor |
| US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
| US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
| US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| KR101029705B1 (en) * | 2010-06-30 | 2011-04-18 | (주)엔솔테크 | Novel peptide and uses thereof |
| US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
| US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
| US20160000682A1 (en) | 2014-07-02 | 2016-01-07 | Geoffrey Brooks Consultants Llc | Peptide-Based Compositions and Methods of Use |
| JP6851965B2 (en) | 2014-09-26 | 2021-03-31 | サハイ バートナガール ラジェンドラ | Inhibitors of NF Kappa B activity for the treatment of diseases and disorders |
| US9943566B2 (en) * | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| US20200179490A1 (en) * | 2016-07-18 | 2020-06-11 | University Of Delaware | Collagen-mimetic peptide mediated delivery of nucleic acid carriers for efficient delivery from collagen |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5240912A (en) | 1983-05-09 | 1993-08-31 | Todaro George J | Transforming growth factor (TGF) peptides |
| US5284763A (en) | 1985-03-22 | 1994-02-08 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
| IL76079A (en) | 1985-08-13 | 1991-03-10 | Univ Ramot | Collagen implants |
| US4975526A (en) | 1989-02-23 | 1990-12-04 | Creative Biomolecules, Inc. | Bone collagen matrix for zenogenic implants |
| US5178845A (en) | 1988-04-20 | 1993-01-12 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
| US5055447A (en) | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
| US5236905A (en) | 1988-08-25 | 1993-08-17 | Oncogen | In vitro method of inhibition of HIV using transforming growth factor-.beta. |
| US5258029A (en) | 1988-09-29 | 1993-11-02 | Collagen Corporation | Method for improving implant fixation |
| US5268455A (en) | 1989-05-25 | 1993-12-07 | Genentech, Inc. | Process for making biologically active polypeptides based on transforming growth factor-βsequences |
| US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| WO1991002537A1 (en) | 1989-08-14 | 1991-03-07 | The Regents Of The University Of California | Synthetic peptides that enhance cell binding |
| US5635482A (en) * | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US5354736A (en) * | 1989-08-14 | 1994-10-11 | Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US5158934A (en) | 1989-09-01 | 1992-10-27 | Genentech, Inc. | Method of inducing bone growth using TGF-β |
| US5364839A (en) | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
| US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
| US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
| AU671606B2 (en) | 1991-10-31 | 1996-09-05 | Whitehead Institute For Biomedical Research | TGF-beta type receptor cDNAs and uses therefor |
| JP3504263B2 (en) | 1991-11-04 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Recombinant bone morphogenetic protein heterodimers, compositions and uses |
| US5322933A (en) | 1992-05-07 | 1994-06-21 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Crystal structure of TGF-β-2 |
| US5780436A (en) * | 1995-05-01 | 1998-07-14 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| US5661127A (en) | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
-
1998
- 1998-07-10 US US09/113,696 patent/US6638912B2/en not_active Expired - Fee Related
-
1999
- 1999-07-08 WO PCT/US1999/015432 patent/WO2000002916A2/en active Application Filing
- 1999-07-08 AU AU49762/99A patent/AU4976299A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020010134A1 (en) | 2002-01-24 |
| WO2000002916A3 (en) | 2000-04-13 |
| AU4976299A (en) | 2000-02-01 |
| US6638912B2 (en) | 2003-10-28 |
| WO2000002916A2 (en) | 2000-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000002916B1 (en) | PEPTIDE COMPOSITIONS MIMICKING TGF-β ACTIVITY | |
| CA2124583A1 (en) | Synthetic compounds and compositions with enhanced cell binding | |
| Reubi | New specific radioligand for one subpopulation of brain somatostatin receptors | |
| EP0451867B1 (en) | Parathyroid hormone antagonists | |
| Wang et al. | Desmethionine alkylamide bombesin analogs: a new class of bombesin receptor antagonists with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells | |
| AU5018693A (en) | Sustained-release protein formulations | |
| WO1998045427A3 (en) | Insulin-like growth factor agonist peptides | |
| DE602004024041D1 (en) | SOLUBLE HYALURONIDASE GLYCOPROTEIN (SHASEGP), METHOD OF ITS PREPARATION, USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | |
| ES2140082T3 (en) | PEPTIDE COMPOSITIONS WITH ACTIVITY OF A GROWTH FACTOR TYPE. | |
| AU9174398A (en) | Peptides | |
| EP0910342A4 (en) | Temperature sensitive gel for sustained delivery of protein drugs | |
| JP2002527052A5 (en) | ||
| WO2000025725A3 (en) | Functional antagonists of hedgehog activity | |
| AU6933496A (en) | Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers | |
| Palaszynski | Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor | |
| PT71861B (en) | Process for preparing long lasting agonists and agonists of lhrh | |
| AU4363199A (en) | Use of hmg proteins for the preparation of medicaments having cytotoxic activity | |
| CA2182795A1 (en) | Superactive vip antagonists | |
| EP1668030A4 (en) | A method of improving efficacy of biological response-modifying proteins and the exemplary muteins | |
| AU726663B2 (en) | SCF analog compositions and methods | |
| LTIP610A (en) | Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds | |
| AU3258197A (en) | Peptides | |
| PL355852A1 (en) | Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients | |
| JO1999B1 (en) | LH-RH' peptide and analogues their uses and pharmaceutical composition containing them | |
| Audhya et al. | Cooperativity of thymopoietin 32–36 (the active site) and thymopoietin 38–45 in receptor binding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN JP KR NZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN JP KR NZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: B1 Designated state(s): AU CA CN JP KR NZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 122 | Ep: pct application non-entry in european phase |